INTRODUCTION: Interferon-β (IFNß) is the first-line treatment for relapsing-remitting multiple sclerosis. Myxovirus resistance protein A (MxA) is a marker of IFNß bioactivity, which may be reduced by neutralizing antibodies (NAbs) against IFNß. The aim of the study was to analyze the kinetics of MxA mRNA expression during long-term IFNβ treatment and assess its predictive value. METHODS: A prospective, observational, open-label, non-randomized study was designed in multiple sclerosis patients starting IFNß treatment. MxA mRNA was assessed prior to initiation of IFNß therapy and every three months subsequently. NAbs were assessed every six months. Assessment of relapses was scheduled every three months during 24 months of follow up. The disease activity was correlated to the pretreatment baseline MxA mRNA value. In NAb negative patients, clinical status was correlated to MxA mRNA values. RESULTS: 119 patients were consecutively enrolled and 107 were included in the final analysis. There was no correlation of MxA mRNA expression levels between baseline and month three. Using survival analysis, none of the selected baseline MxA mRNA cut off points allowed prediction of time to first relapse on the treatment. In NAb negative patients, mean MxA mRNA levels did not significantly differ in patients irrespective of relapse status. CONCLUSION: Baseline MxA mRNA does not predict the response to IFNß treatment or the clinical status of the disease and the level of MxA mRNA does not correlate with disease activity in NAb negative patients.

Department of Medical Microbiology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Department of Neurology and Center of Clinical Neuroscience Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Department of Neurology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Laboratory of Molecular Diagnostics Na Homolce Hospital Prague Czech Republic

Zobrazit více v PubMed

Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004; 56(4): 548–555. 10.1002/ana.20224 PubMed DOI

Bertolotto A, Granieri L, Marnetto F, Valentino P, Sala A, Capobianco M, et al. Biological monitoring of IFN-β therapy in Multiple Sclerosis. Cytokine and Growth Factor Rev. 2015; 26(2): 241–248. PubMed

Ronni T, Melen K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol. 1993; 150(5): 1715–1726. PubMed

van der Voort LF, Visser A, Knol DL, Oudejans CBM, Polman CH, Killestein J. Lack of IFN-beta bioactivity is associated with the occurence of relapses in multiple sclerosis. Eur J Neurol. 2009; 16(9): 1049–1052. 10.1111/j.1468-1331.2009.02649.x PubMed DOI

Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008; 70(13 Pt 2): 1119–1127. 10.1212/01.wnl.0000304040.29080.7b PubMed DOI

Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, et al. Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001; 256(1–2): 141–152. PubMed

Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009; 73(5): 372–377. 10.1212/WNL.0b013e3181b04c98 PubMed DOI

Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, Di Sapio A, et al. Anti-interferon beta neutralising activity is not entirely mediated by antibodies. J Neuroimmunol. 2007; 192(1–2): 198–205. 10.1016/j.jneuroim.2007.09.025 PubMed DOI

Serana F, Imberti L, Amato MP, Comi G, Gasperini C, Ghezzi A, et al. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS One. 2014; 9(4): e94794 10.1371/journal.pone.0094794 PubMed DOI PMC

Baarsen LGM, Vosslamber S, Tijssen M, Baggen JMC, van der Voort LF, Killestein J, et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One. 2008; 3(4): e1927 10.1371/journal.pone.0001927 PubMed DOI PMC

Baranzini SE, Madireddy LR, Cromer A, D'Antonio M, Lehr L, Beelke M, et al. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients. Mult Scler. 2015; 21(7): 894–904. 10.1177/1352458514555786 PubMed DOI

Verweij CL, Vosslamber S. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med. 2013; 15(80): 51–60. PubMed

Matas E, Bau L, Martinez-Iniesta M, Romero-Pinel L, Alba Mane M, Cobo-Calvo A, et al. Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PLoS One. 2014; 9(11): e112758 10.1371/journal.pone.0112758 PubMed DOI PMC

Polman CH, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol. 2011; 69(2): 292–302. 10.1002/ana.22366 PubMed DOI PMC

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25(4): 402–408. 10.1006/meth.2001.1262 PubMed DOI

Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res. 2001; 21(9): 729–742. 10.1089/107999001753124462 PubMed DOI

Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res. 2001; 21(9): 743–755. 10.1089/107999001753124471 PubMed DOI

Maria NI, Brkic Z, Waris M, Helden-Meeuwsen CG, Heezen K, van de Merwe JP, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren´s syndrome. Ann Rheum Dis. 2014; 73(6): 1052–1059. 10.1136/annrheumdis-2012-202552 PubMed DOI PMC

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5): 2610–2615. 10.1073/pnas.0337679100 PubMed DOI PMC

van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, Barkhof F, et al. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 2010; 75(14): 1228–1233. 10.1212/WNL.0b013e3181f6c556 PubMed DOI

Vosslamber S, van Baarsen LGM, Verweij CL. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics. 2009; 10(1): 97–108. 10.2217/14622416.10.1.97 PubMed DOI

Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264(5167): 1918–1921. PubMed

Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis. 1994; 169(4): 807–813. PubMed

Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J, et al. IFN-beta 1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008; 28(5): 317–331. 10.1089/jir.2007.0131 PubMed DOI

Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain. 2003; 126(Pt 6): 1419–1429. PubMed

Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol. 2003; 171(5): 2694–2702. PubMed

Comabella M, Luenemann JD, Rio J, Sanchez A, Lopez C, Julia E, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009; 132(Pt 12): 3353–3365. 10.1093/brain/awp228 PubMed DOI

Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, et al. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol. 2011; 258(5): 895–903. 10.1007/s00415-010-5844-5 PubMed DOI

Creeke PI, Farrell RA. Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis. Ther Adv Neurol Disord. 2013; 6(1): 3–17. 10.1177/1756285612469264 PubMed DOI PMC

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler. 2014; 20(5): 577–587. 10.1177/1352458513503597 PubMed DOI

Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano F, Di Sapio A, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry. 2004; 75(9): 1294–1299. 10.1136/jnnp.2004.037259 PubMed DOI PMC

Oliver-Martos B, Orpez T, Pinto-Medel MJ, Mayorga C, Garcia-Leon JA, Maldonado-Sanchez R, et al. Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patiens. J Neuroimmunol. 2011; 230(1–2): 153.–. 10.1016/j.jneuroim.2010.10.033 PubMed DOI